Regenxbio
ProfileJobs (22)

Regenxbio

Suggest Editwdxefcqufszuzezftuxetqsqxt
    • Healthcarebiotechgeneticshealthtechpharma
    Regenx Biosciences, LLC, a biopharmaceutical company, develops therapeutics and research tools based on adeno-associated viral (AAV) vectors. The Company offers NAV, a gene delivery technology that includes recombinant adeno-associated viral vectors. Its technology is used for the treatment of metabolic disorders, muscle diseases, hematologic disorders, ocular diseases, and neurodegenerative disorders; and clinical trails in therapeutic areas, such as inherited diseases, CNS disorders, heart failure, and vaccines. The Company also offers reagent services for various applications, including molecular therapies, understanding biological activity and target validation, creating disease models and screening in vivo, and genome-wide association studies. In addition, Regenxoffers custom products and services, including AAV plasmids, AAV Vector reporter systems, and custom AAV vectors to the researchers.
    Revenue(FY, 2017)
    $10.4 M
    Market capitalization(2018-09-20)
    $2.3 B
    TypePublic
    HQRockville, US
    Founded2009
    Size (employees)107 (est)+13%
    Websiteregenxbio.com
    Regenxbio was founded in 2009 and is headquartered in Rockville, US
    Report incorrect company information

    Viewing summary data as a guest

    Sign up for free to see all data

    Key People/Management at Regenxbio

    Ken Mills

    Ken Mills

    President and Chief Executive Officer
    Vit Vasista

    Vit Vasista

    CFO
    Stephen Yoo

    Stephen Yoo

    Chief Medical Officer
    Olivier Danos

    Olivier Danos

    Chief Scientific Officer
    Curran Simpson

    Curran Simpson

    Senior Vice President, Technical Operations
    Kimberly Sloan

    Kimberly Sloan

    Senior Vice President, Human Resources
    Show more

    Regenxbio Office Locations

    Regenxbio has an office in Rockville
    Rockville, US (HQ)
    100 9712 Medical Center Dr
    Show all (1)
    Report incorrect company information

    Regenxbio Financials and Metrics

    Regenxbio Revenue

    Regenxbio's revenue was reported to be $10.39 m in FY, 2017
    USD

    Revenue (Q2, 2018)

    		172.4 m

    Gross profit (Q2, 2018)

    		166.1 m

    Gross profit margin (Q2, 2018), %

    		96.4%

    Net income (Q2, 2018)

    		114.8 m

    EBIT (Q2, 2018)

    		108.4 m

    Market capitalization (20-Sep-2018)

    		2.3 b

    Closing stock price (20-Sep-2018)

    		71.6

    Cash (30-Jun-2018)

    		106.9 m
    Regenxbio's current market capitalization is $2.3 b.
    Annual
    USDFY, 2017

    Revenue

    		10.4 m

    General and administrative expense

    		27.2 m

    R&D expense

    		57.2 m

    Operating expense total

    		86.3 m
    Quarterly
    USDQ1, 2018Q2, 2018

    Revenue

    		132.4 m172.4 m

    Cost of goods sold

    		6.3 m

    Gross profit

    		166.1 m

    Gross profit Margin, %

    		96%
    show all
    Annual
    USDFY, 2017

    Cash

    		46.7 m

    Accounts Receivable

    		473 k

    Current Assets

    		168 m

    PP&E

    		14 m
    Quarterly
    USDQ1, 2018Q2, 2018

    Cash

    		71.9 m106.9 m

    Accounts Receivable

    		26 m739 k

    Current Assets

    		262.7 m293.3 m

    PP&E

    		14.8 m16.7 m
    show all
    Annual
    USDFY, 2017

    Net Income

    		(73.2 m)

    Depreciation and Amortization

    		2.7 m

    Accounts Payable

    		2.6 m

    Cash From Operating Activities

    		(58 m)
    Quarterly
    USDQ1, 2018Q2, 2018

    Net Income

    		104.2 m114.8 m

    Depreciation and Amortization

    		834 k1.7 m

    Accounts Payable

    		477 k(340 k)

    Cash From Operating Activities

    		58.1 m128.3 m
    show all
    USDY, 2018

    Financial Leverage

    		1.1 x
    Show all financial metrics
    Report incorrect company information

    Competitors

    Alnylam Pharmaceuticals
    Healthcare - Public
    Arbutus Biopharma
    Healthcare - Public
    Encoded Genomics
    Healthcare - Private
    Precision NanoSystems
    Healthcare - Private
    Compare competitors

    Regenxbio Online and Social Media Presence

    Embed Graph
    Report incorrect company information

    Regenxbio News and Updates

    June 05, 2018

    Optogenetic Market 2018 Enthralling Growth at A CAGR Of 17% | By Product Type Light Instruments, Actuators, Sensors – Declares MRFR

    This report provides in-depth qualitative and overall analysis of the” Optogenetic Market” on a global and regional level from 2018 to 2023. The study also provides a comprehensive review of restraints, Market Dynamics, drivers and opportunities along with their impact on the overall market. The rep…
    May 06, 2018

    3 Things In Biotech, May 5: Mallinckrodt Snubbed, Regenxbio Races, Portola Surprises

    April 18, 2018

    OncoSec: The Underlying Science Of ImmunoPulse Powers A Potential Winner

    April 17, 2018

    Rounds Report: Regenxbio Surged Higher While Celldex Tumbled Due To A Negative Clinical Binary

    April 10, 2018

    BioSci Rounds Report: Regenxbio Surged, Geron Trading Reversed And Dexcom G6 Approved

    December 21, 2017

    Optogenetic Market Demonstrate Immense Growth Potential at ~176% of CAGR By 2023

    This study covers the market dynamics and trends in major countries that are expected to influence the current market scenario and future status of the global Optogenetic Market over the forecast period. Posted via Industry Today. Follow us on Twitter @IndustryToday
    Report incorrect company information

    Regenxbio Company Life and Culture

    Report incorrect company information
    Download PDF